about
Creating an effective clinical registry for rare diseasesA polycystin-centric view of cyst formation and disease: the polycystins revisitedSpanish guidelines for the management of autosomal dominant polycystic kidney diseaseMicroRNAs and benign biliary tract diseasesPolycystic liver diseases: advanced insights into the molecular mechanismsLiver masses: a clinical, radiologic, and pathologic perspective.Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient dataPolycystic liver disease: an overview of pathogenesis, clinical manifestations and management.Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.Functional Budd-Chiari Syndrome Associated With Severe Polycystic Liver Disease.Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.MicroRNAs in Cholangiopathies.Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trialInhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseasesMedical therapy for polycystic liver disease.Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.A Lumpy Bumpy Liver.Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.Evidence for a role of proteins, lipids, and phytochemicals in the prevention of polycystic kidney disease progression and severity.Renal transplantation in autosomal dominant polycystic kidney disease.Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up.Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy.Center is an important indicator for choice of invasive therapy in polycystic liver disease.Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.Polycystic Liver Disease: The Benefits of Targeting cAMP.Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes.Weight loss in a patient with polycystic kidney disease: when liver cysts are no longer innocent bystanders.The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.Impact of liver volume on polycystic liver disease-related symptoms and quality of life.Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial.[Modern diagnostics of cystic liver lesions and hemangiomas].Severe Polycystic Liver Disease Is Not Caused by Large Deletions of the PRKCSH Gene.A novel twist in polycystic liver diseaseDrug holiday in patients with polycystic liver disease treated with somatostatin analogues
P2860
Q26741126-526CCFAA-24F8-404A-BC77-722E2F9FD5F1Q26800974-D259DD77-B086-4340-84A2-97B5AC40A83EQ26863397-7B8C6020-D1BD-42A4-97CC-281B195A6148Q26865762-ADFE79FE-9CD0-4D34-9BB1-F85718443D79Q27001174-C259D27A-8B52-4F62-A5B1-8285350185EFQ30403670-13A5EC01-5F4A-4F40-876C-8467FF6408B8Q31096193-F15D6868-B3FF-43F7-A1B1-D91F73298342Q33648233-5A368BC4-B839-4712-9670-EE3975789596Q33702355-1BAD72F3-3EC5-4BF0-BF53-0EA8FEC1F636Q33783831-52A70419-5DA3-4FD0-8C63-45E7474FDAE7Q33873050-082EAFC7-4EF3-4BE1-8621-F926B50352D0Q33991899-732B6C50-753E-4E59-9583-7B37FE5BEC91Q35163905-246B2916-91A2-4097-992E-5E18E6C93074Q35185224-E7B4777D-6536-4597-92AA-C8AB3511B4E8Q35873958-96072900-ED1E-45D6-8818-36F2ECD481DAQ36075389-F05EA0AE-DA9B-4ED2-AA8D-EE00BFC2A694Q37029861-64A82E1B-4ED5-4FFD-A6AB-A40436796F8EQ37311498-AD42CF1E-29B7-4386-A581-AFA33FCBBE6EQ37415464-A4D2C3E7-1111-470F-B30B-67F1CF809CF8Q37620079-1989367C-10CC-4FA9-8C2E-94E39ABAF9B8Q38163610-1DA1664E-D40E-49E1-AEF5-8F3354C1E69DQ38220783-157DEC72-F740-471F-B6C0-9CA79EB0F9B8Q38641525-90E8C66B-E60A-4D90-8B71-590B37233994Q38737946-9CBA878D-20C2-4054-A30C-EB0D5AF986E9Q38860122-CE0436F8-1750-4223-84E1-637408BBEDDCQ39299052-E5B88312-278D-438E-B80F-ECE74FACDDB3Q40780575-D427B855-CEB4-4261-ABD1-8F064E5CAEF8Q42634983-CC775E34-AC8D-4CCB-BE5C-8C57BD1AC628Q47137161-DE496530-AEBB-407B-A408-8F741098E3E1Q47394138-90CECE9D-FB91-469E-99DC-27D019F12385Q47648297-A8F9295A-88A7-47FF-89AF-7CFAA893CB7AQ48121526-C0B07835-B9F8-4ACD-8AC8-4AC7452F5234Q50052506-94274E06-44FD-428D-A59B-32A72F272143Q50110106-BEE4A775-E61E-44D0-847A-9166E6A16413Q53031386-C6C68A35-0751-46D8-8B18-73326EC81D5BQ55043077-06A0D00D-60EE-4E04-B454-F88D8979D78FQ57149503-D3357206-C2C2-4698-80CF-8ADA38FB7680Q57298238-70710D81-134C-4CCC-9B66-F08D2DF373CB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Diagnosis and management of polycystic liver disease.
@en
type
label
Diagnosis and management of polycystic liver disease.
@en
prefLabel
Diagnosis and management of polycystic liver disease.
@en
P2860
P1476
Diagnosis and management of polycystic liver disease.
@en
P2093
Joost P H Drenth
Tom J G Gevers
P2860
P2888
P304
P356
10.1038/NRGASTRO.2012.254
P407
P577
2013-01-08T00:00:00Z
P6179
1018266999